Related Experiment Video

Updated: May 22, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip

Marek Minarik1, Marta Kopeckova, Marcus Gassman

  • 1Center for Applied Genomics of Solid Tumors, Genomac Research Institute, Prague, Czech Republic. mminarik@email.com

Electrophoresis
|May 17, 2012
PubMed

Insights

This study introduces a new, cost-effective genotyping method for identifying clopidogrel resistance. This approach helps personalize antiplatelet therapy for patients with cardiovascular disease by detecting key genetic variations.

Area of Science:

  • Pharmacogenomics
  • Molecular diagnostics

Background:

  • Antiplatelet therapy, particularly clopidogrel, is crucial for cardiovascular disease management.
  • Clopidogrel metabolism relies on Cytochrome P450 enzymes, and genetic variations (polymorphisms) can lead to treatment resistance.
  • Current genotyping methods for clopidogrel resistance can be time-consuming or complex.

Purpose of the Study:

  • To develop and validate a novel, rapid, and cost-effective genotyping method for identifying clopidogrel resistance-associated polymorphisms.
  • To optimize allele separation for specific CYP2C19 and CYP2C9 gene variants using denaturing capillary electrophoresis on a Bioanalyzer chipCE platform.

Main Methods:

  • Utilized denaturing capillary electrophoresis combined with Bioanalyzer chipCE technology.
  • Optimized allele separation for CYP2C19 I331V, CYP2C9 R144C, and CYP2C9 I359L polymorphisms.
  • Employed upgraded heater control with run temperatures up to 55°C.

Main Results:

  • Demonstrated a rapid and reproducible method for genotyping clopidogrel resistance polymorphisms.
  • Achieved successful allele separation for targeted CYP gene variants.
  • The developed approach is accessible, feasible, and cost-effective.

Conclusions:

  • The new genotyping approach offers a practical solution for identifying patients resistant to clopidogrel therapy.
  • This method facilitates personalized antiplatelet treatment strategies in cardiovascular care.
  • The technique combines analytical power with speed and ease of use for clinical application.

More Related Videos

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format05:58

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...